A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The intent of this study is to identify and treat fibromyalgia subjects with comorbid
depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI
(selective norepinephrine reuptake inhibitor) primarily for their depression and to determine
whether pregabalin demonstrates improvement relative to placebo in improving pain associated
with fibromyalgia.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.